OOIR: Observatory of International Research

Papers

(The H4-Index of Hypertension Research is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19	288
COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study	133
Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19	120
Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China	88
Downregulation of ACE2 induces overstimulation of the renin–angiotensin system in COVID-19: should we block the renin–angiotensin system?	85
Blood pressure variability: its relevance for cardiovascular homeostasis and cardiovascular diseases	63
Uric acid and hypertension	58
Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial	57
Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension	51
Epidemiology of hypertension in Japan: beyond the new 2019 Japanese guidelines	48
Decoding the functional role of long noncoding RNAs (lncRNAs) in hypertension progression	46
A novel COVID-19 and its effects on cardiovascular disease	45
Renin–angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study	41
Seasonal variation in blood pressure: current evidence and recommendations for hypertension management	39
Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction	37
Effects of renal denervation on blood pressures in patients with hypertension: a systematic review and meta-analysis of randomized sham-controlled trials	35
Renal denervation: basic and clinical evidence	33
Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study	32
Nighttime home blood pressure as a mediator of N-terminal pro-brain natriuretic peptide in cardiovascular events	32
MitomiRs: new emerging microRNAs in mitochondrial dysfunction and cardiovascular disease	32
Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19	31
Low birth weight trends: possible impacts on the prevalences of hypertension and chronic kidney disease	30
Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease	30
Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies	30
Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism	28

U-shaped relationship between serum uric acid level and decline in renal function during a 10-year period in female subjects: BOREAS-CKD2	27
Impact of the COVID-19 pandemic on blood pressure control: a nationwide home blood pressure monitoring study	26
The WNK signaling pathway and salt-sensitive hypertension	26
Hypertensive disorders of pregnancy: definition, management, and out-of-office blood pressure measurement	26
SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs	26